Letters
We welcome the opportunity to respond to the letter by Wald et al. and to comment on the points they raised.
Point 1
Wald et al. estimated from our Fig. 2 that the proportion of cases greater than 2 MoM are higher at gestations greater than 16 weeks and suggest that this is directly opposite to those we stated in Table 9 .
1 Wald et al. misunderstand the data in Table 9 , which contains detection rate data based on the use of three parameters-maternal age, o-fetoprotein (AFP) and free (3 hCG concentrations; this data cannot be directly compared with Fig. 2 . However, on re-examination on Fig. 2 and its associated data we did find that this figure contained two errors: there are 91 points plotted rather than the 90 that should be and two cases plotted at 16 weeks should have been at 17 weeks.
When the actual data is examined, the median Free (3-hCG in Down's syndrome cases at the [14] [15] [16] weeks' gestation period was 2·52 and at greater than 16 weeks was 2' 32. The corresponding median for AFP in these two groups was o· 66 and 0'73 and the mean age was 30·9 and 30'2 years, respectively. The enhanced detection seen in early gestation is therefore a function of the higher median free (3 hCG and the marginally lower median AFP and not as suggested by Wald et al., confounded by maternal age. Table 9 of our paper showed also that the added benefit of increased detection efficiency using free (3-hCG compared with total hCG was indeed greater in the earlier weeks (15'6% versus 8,3%) . This difference cannot be attributed to age, since age should have had a similar effect on Detection Rate with both analytes, This serves to further demonstrate that the difference between free (3-hCG and total hCG is greater in the earlier gestational period.
A new study to be published shortly' also confirms that the median free (3-hCG levels in Down's syndrome cases does appear higher in the earlier weeks compared with that at [17] [18] [19] [20] [21] [22] weeks. This difference between free {3 hCG and total hCG is precisely consistent with our observations of elevated free (3 hCG levels during the first trimesterv' at a time when levels of total hCG are not elevated. ' With respect to the issue of false positive rate (FPR) once again we confirm that our data showed only a marginal (0'3%) higher FPR in the early gestation group. In summary: (i) the estimate of 770/0 detection in the paper is uninterpretable taken by itself; (ii) estimates of free {3-hCG reported as showing an extra 10% detection over total hCG are exaggerated; (iii) the data in the study yielded 6% extra detection for free {3-hCG alone over total hCG alone, at a 5% false-positive rate; (iv) when applied to the population age distribution of births and used with maternal age and AFP free {3-hCG yielded 3% less detection than total hCG if an appropriate correction is made for the failure of the data adequately to fit a Gaussian distribution; (v) free (3-hCG yielded 1% more detection than total hCG if uE) was used as well; (vi) the addition of uE) to free {3-hCG, AFP and maternal age increases the detection rate by about 7%.
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Point 2
We have re-perforrned our calculations for our Table 7 (which is based on actual observed data) and Table 8 (which is based on modelled data) and obtain the same data as that previously published.' Indeed our assertion of a 10070 increase in detection rate has been further confirmed by Professor's Cuckle and Lilford:" these authors have also modelled our population parameters against the age distribution of pregnancies in England and Wales and showed that at a 5% FPR there is a 8-10% higher predicted detection rate using free {j-hCG rather than total hCG. We suggest that there may be differences in the way that our three groups model the data which results in the Wald et at. data being at variance with those of Cuckle and Lilford and our own published estimates. Standard deviate
Point 4
The use of actual sample data rather than the smoothed data modelled in 
Point 3
Wald et at. point to the use of truncation limits while much of their previously published population parameters are based on smoothing and adjustments to their data. For example they estimate the population standard deviation by taking the difference between the 10th and 90th centile divided by 2'563, thus excluding from the estimate 20070 of the observed data. In calculating correlation between analytes, outlier exclusion is used as it is also used in testing for Gaussian normality. The net effect of this 'smoothing' is to make for a very idealized model and is likely to result in overestimation of the performance which would be found in routine screening.
With respect to free {j-hCG, Wald et at.
maintain that the distribution of free (j-hCG MoM deviates from a Gaussian distribution beyond 3· 0 MoM after a log transformation, and that when applying truncation limits of 0'33-3'OOMoM a 5070 lower detection rate is achieved. Wald et at. do not state the origin of this data, or indeed provide the sample history from which they make such claims, and no evidence is provided to substantiate the claim of nonlinearity and the need for truncation. Indeed, our own published data? from over 6000 prospectively collected unaffected samples has shown no such deviation from linearity at 5 MoM and linearity observed in a further study of the dual analyte assay in six UK centres! has shown linearity in 1500 unaffected cases to be at least to 7 MoM with 168 Down's cases showing linearity even at the extremes of 10 MoM. Figure 1 shows further data from other centres, both sets of data Point S The distributions in the tables are consistent with the curves in our Fig. 3 with the exception that the last point for total hCG should be at a FPR of 11.90/0. This does not materially alter the point of our Fig. 3 , which clearly demonstrates that free {3-hCG has more Down's discriminating power alone than either AFP, UE] or total hCG. The 10th centile for AFP given in the text should be O:50 and appears to have been missed at the proof stage, as does an error in our Table  2 1 which shows that with results = >2'8 MoM the % of Down's cases should be 45 . 5 not 46· 7 .
The 10th centile and 90th centile for AFP and UE] and the data related to our Tables 4 and 51 show similarity with data published previously by Wald et al. 15 as shown in Table 1 . If, therefore, our population parameters in our earlier Table 6 are closer to the consensus estimates for AFP and 
15
The real test of any screening programme is not based on mathematical modelling of retrospective data and adjustments or estimates of the 'real world', but is based on true prospective experience. In three of our four centres, prospective screening using AFP and free {3-hCG has been in use (using the population data shown in our original Table 6 ) for over 18 months. Table 2 shows the current performance achieved in prospective practice. We believe these screening performance figures confirm our predictions based on our retrospective study, especially when compared with the prospective performance achieved by Wald et al. 16 of 48% detection and the 58% detection achieved by Haddow et al. 17 using 'triple screening'.
In summary, Wald et al. offer comments on our paper based on theory. We presented a sizeable amount of empirical data, in addition we also provided results based on statistical modelling. The effectiveness of 'triple marker' screening by Wald et al. 18 predicted a detection of 60% for Down's syndrome based on modelling. Even though they could have presented empirical data they chose not to do so. The 60% detection efficiency resulting from this model was promoted as a benchmark for 'triple screening' , although even Wald et al. 16 have not found this achievable in practice.
Based on real data from our study the free {3-hCG and AFP two analyte protocol achieved better performance than 'triple screening'. By presenting both empirical and modelling data we have given the screening community more information than others to evaluate independently the best protocol for Down's syndrome screening. 
